Immune Response to Varicella-Zoster Vaccination and Infection
Completed
Conditions studied: Chickenpox, Herpes Zoster
In brief
Background: * The common varicella-zoster virus causes both chickenpox and shingles. Both diseases cause rashes, but they can also have complications such as bacterial infections of the skin, pneumonia, or eye disease. * By drawing and studying blood samples from people who have been infected with the varicella-zoster virus or who are receiving or have received the varicella vaccine, researchers hope to learn more about the immune system s response to the virus. Objectives: \- To determine the immune system s response to the varicella virus, either in its existing form or given as part of a vaccine. Eligibility: * Individuals 18 years of age and older who have had or are receiving the varicella vaccine. * Individuals 5 years of age and older who currently have chickenpox or shingles. Design: * Participants will visit the NIH Clinical Center for an initial physical examination, and will provide blood samples for evaluation. * Researchers will determine the number of samples to be taken and the amount of blood to be drawn as needed based on the participants medical history and exposure to the varicella-zoster virus. Investigators in this study will not be giving subjects either the chickenpox or shingles vaccine. They will only be looking at the response to the vaccine in persons who are receiving or have received the vaccine from their health care provider.
Key facts
- Study ID
- NCT00921999
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 19
- Starts
- 2009-06-15
- Expected to finish
- 2015-01-08
- Last updated by the study team
- 2018-02-14
Who can join
Age: 5 and older. Sex: any. Healthy volunteers: accepted.
You may not qualify if…
- Study subjects will be excluded if they fulfill either of the following criteria:
- Active substance abuse or history of prior substance abuse that may interfere with protocol compliance or compromise patient safety (Groups I, II, IV who will be providing several blood samples)
- History of chickenpox, zoster, or having received the zoster vaccine for patients in Groups I, II or III.
- Patients in group I found to have a hemoglobin <11 gm/dl will be reassigned to group II or terminated from the study.
Where it is running
- National Institutes of Health Clinical Center, 9000 Rockville Pike — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.